Complications of Coronavirus Disease-19 in a Hospitalized Patient: A Case Report
DOI:
https://doi.org/10.3889/oamjms.2020.5615Keywords:
pandemics, intensive care, lungs, corona virus, treatment, prevention, SARS-CoV-2Abstract
BACKGROUND: Coronavirus (CoV) disease (COVID)-19 infection is a major public health issue worldwide with no specific therapy or vaccine.
CASE REPORT: COVID-19-positive patient was hospitalized due to a dry irritating cough that has persisted for 3 days. The polymerase chain reaction test to severe acute respiratory syndrome-CoV-2 was positive. Computed tomography (CT) scan of the lungs showed massive bilateral consolidation. The patient was set to oxygen support (6 L/min). Two hours after referring the patient’s condition worsened with shortness of breath, suffocation, wheezing, and decreased saturation (77%). The patient was given mechanical support with continuous positive airway pressure mask. Therapy included azithromycin 500 mg and ceftriaxone 2 g. On the 3rd day of hospitalization, there was a sharp deterioration of the condition and a decrease in saturation (40%). The patient was intubated and immediately placed on intermittent positive pressure ventilation. Azithromycin was now combined with meropenem 3 × 1 g. The next morning patient’s condition further worsened with decrease in saturation and heart rate. The resuscitation was unsuccessful.
CONCLUSION: COVID-19 is primary a respiratory infection, but the virus also affects other organs with poor outcome.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
World Health Organization Regional Office for Europe. WHO Coronavirus Disease (COVID-19) Dashboard. Copenhagen: World Health Organization (WHO) Regional Office for Europe; 2020. Available from: https://www.covid19.who.int. [Last accessed on 2020 Dec 18]. https://doi.org/10.1093/ annhyg/2.2.160
Министерство за здравство на РСМ. Коронавирус. Скопје: Министерство за здравство на РСМ; 2020. Available from: http://www.zdravstvo.gov.mk/korona-virus. [Last accessed on 2020 Dec 18].
World Health Organization Regional Office for Europe. Coronavirus Disease (COVID-19) Pandemic. Copenhagen: World Health Organization (WHO) Regional Office for Europe; 2020. Available from: https://www.euro.who.int/en/health-topics/ health-emergencies/coronavirus-covid-19/novel-coronavirus2019-ncov. [Last accessed on 2020 Dec 18]. https://doi.org/10.1016/j.wneu.2020.03.068 DOI: https://doi.org/10.1016/j.wneu.2020.03.068
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324(8):782-93. https://doi.org/10.1001/jama.2020.12839 PMid:32648899 DOI: https://doi.org/10.1001/jama.2020.12839
National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Symptoms of Coronavirus. Atlanta, GE: Centers for Disease Control and Prevention (CDC); 2020. Available from: https://www.cdc.gov/coronavirus/2019- ncov/symptoms-testing/symptoms.html. [Last accessed on 2020 Dec 18].
Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. https://doi.org/10.1016/j.cpcardiol.2020.100618 PMid:32439197 DOI: https://doi.org/10.1016/j.cpcardiol.2020.100618
World Health Organization. How is COVID-19 Transmitted? Geneva: World Health Organization; 2020. Available from: https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/ question-and-answers-hub. [Last accessed on 2020 Dec 18].
World Health Organization. Coronavirus Disease (COVID-19) Advice for the Public. Geneva: World Health Organization; 2020. Available from: https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/advice-for-public. [Last accessed on 2020 Dec 18].
Centers for Disease Control and Prevention. How to Protect Yourself and Others. Atlanta, GE: Centers for Disease Control and Prevention (CDC); 2020. Available from: https://www.cdc. gov/coronavirus/2019-ncov/prevent-getting-sick/prevention. html. [Last accessed on 2020 Dec 18]. https://doi.org/10.1093/ofid/ofv131.60 DOI: https://doi.org/10.1093/ofid/ofv131.60
European Centre for Disease Prevention and Control. Diagnostic Testing and Screening for SARS-CoV-2. Solna: European Centre for Disease Prevention and Control (ECDC); 2020. Available from: https://www.ecdc.europa.eu/en/covid-19/ latest-evidence/diagnostic-testing. [Last accessed on 2020 Dec 18]. https://doi.org/10.2807/1560-7917.es.2020.25.8.2002271 DOI: https://doi.org/10.2807/1560-7917.ES.2020.25.8.2002271
Cennimo DJ, Bergman SJ, Olsen KM. What is the Role of CT Scanning in the Diagnosis of Coronavirus Disease 2019 (COVID-19)? Available from: https://www.medscape.com/ answers/2500114-197443/what-is-the-role-of-ct-scanning-inthe-diagnosis-of-coronavirus-disease-2019-covid-19. [Last accessed on 2020 Dec 18]. https://doi.org/10.2214/ajr.20.22954 DOI: https://doi.org/10.2214/AJR.20.22954
Torneri A, Libin P, Vanderlocht J, Vandamme AM, Neyts J, Hens N. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. BMC Med. 2020;18(1):191. https://doi.org/10.1186/s12916-020-01636-4 PMid:32586336 DOI: https://doi.org/10.1186/s12916-020-01636-4
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14(3):241-6. https://doi.org/10.1016/j.dsx.2020.03.011 PMid:32247211 DOI: https://doi.org/10.1016/j.dsx.2020.03.011
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71. https://doi.org/10.1038/s41422-020-0282-0 DOI: https://doi.org/10.1038/s41422-020-0282-0
Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus. Int J Antimicrob Agents. 2020;55(3):105923. https://doi.org/10.1016/j.ijantimicag.2020.105923 PMid:32070753 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105923
Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/ lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218-32. https://doi.org/10.1074/jbc.m116.716100 PMid:26953343 DOI: https://doi.org/10.1074/jbc.M116.716100
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. https://doi.org/10.5582/bst.2020.01047 PMid:32074550 DOI: https://doi.org/10.5582/bst.2020.01047
Gautret P, Lagiera JC, Parolaa P, Hoanga VT, Meddeba L, Mailhea M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. PMid:32205204 DOI: https://doi.org/10.1016/j.ijantimicag.2020.106063
Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More than just an antimicrobial? Clin Drug Investig. 2020;40:683-6. https://doi.org/10.1007/s40261-020-00933-3 DOI: https://doi.org/10.1007/s40261-020-00933-3
Agarwal AD. Azithromycin in coronavirus disease-19: What we know? Open Access Maced J Med Sci. 2020;8:92-6. https://doi.org/10.3889/oamjms.2020.4843 DOI: https://doi.org/10.3889/oamjms.2020.4843
Oldenburg CE, Doan T. Azithromycin for severe COVID-19. Lancet. 2020;396(10256):936-7. https://doi.org/10.1016/s0140-6736(20)31863-8 PMid:32896293 DOI: https://doi.org/10.1016/S0140-6736(20)31863-8
Feola DJ, Garvy BA, Cory TJ, Birket SE, Hoy H, Hayes D Jr., et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob Agents Chemother. 2010;54(6):2437- 47. https://doi.org/10.1128/aac.01424-09 PMid:20231397 DOI: https://doi.org/10.1128/AAC.01424-09
Li H, Liu DH, Chen LL, Zhao Q, Yu YZ, Ding JJ, et al. Metaanalysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58(1):511-7. https://doi.org/10.1128/aac.02067-13 PMid:24189261 DOI: https://doi.org/10.1128/AAC.02067-13
World Health Organization. Q and A on Coronaviruses (COVID-19). Geneva: World Health Organization; 2020. Available from: https://www.who.int/emergencies/diseases/ novel-coronavirus-2019/question-and-answers-hub/q-a-detail/ q-a-coronaviruses#:~:text=symptoms. [Last accessed on 2020 Dec 18].
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. DOI: https://doi.org/10.1056/NEJMoa2002032
Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kali AC, et al. Remdesivir for the treatment of Covid-19: Preliminary report. N Engl J Med. 2020;383(19):1813-26. PMid:32445440
Bush A, Cunningham S, de Blic J, Barbato A, Clement A, Epaud R, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax. 2015;70(11):1078- 84. https://doi.org/10.1136/thoraxjnl-2015-207349 PMid:26135832 DOI: https://doi.org/10.1136/thoraxjnl-2015-207349
Cai M, Bonella F, Dai H, Sarria R, Guzman J, Costabel U. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology. 2013;218(6):930-7. https://doi.org/10.1016/j.imbio.2012.10.014 PMid:23199585 DOI: https://doi.org/10.1016/j.imbio.2012.10.014
Beigelman A, Isaacson-Schmid M, Sajol G, Baty J, Rodriguez OM, Leege E, et al. Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135(5):1171-8. https://doi.org/10.1016/j.jaci.2014.10.001 PMid:25458910 DOI: https://doi.org/10.1016/j.jaci.2014.10.001
Zeng S, Meng X, Huang Q, Lei N, Zeng L, Jiang X, et al. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int J Antimicrob Agents. 2019;53(4):362-9. https://doi.org/10.1016/j.ijantimicag.2018.12.009 PMid:30599241 DOI: https://doi.org/10.1016/j.ijantimicag.2018.12.009
Jin YH, Cai L, Cheng ZS. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019- nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4. https://doi.org/10.1016/j.kint.2020.03.001 PMid:32029004
Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int 2020;97(5):824-8. PMid:32204907 DOI: https://doi.org/10.1016/j.kint.2020.03.001
McIntosh K. Coronavirus Disease 2019 (COVID-19): Epidemiology, Virology, and Prevention. Available from: https:// www.uptodate.com/contents/coronavirus-disease-2019-covid19-epidemiology-virology-clinical-features-diagnosis-andprevention. Published 2020. [Last accessed on 2020 Sep 15]. https://doi.org/10.1007/978-981-15-4814-7 DOI: https://doi.org/10.1007/978-981-15-4814-7
Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol 2020;35(5):744-8. PMid:32215956 DOI: https://doi.org/10.1111/jgh.15047
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Iskra Meshkova, Dragan Mijakoski, Magdalena Simeonova, Zorica Markovska, Vesna Markoska (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
